Commercial Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening Pharmaceutical TechnologySales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.Read full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Technology Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: BMS brings the buzz around late-stage readouts amid a so-so Q1Next: LEO Pharma to acquire gene therapy company Replay Related Stories Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs pharminent June 22, 2026 Commercial The first 14 days: How specialty programs set patients up for success pharminent June 22, 2026 Commercial Denali sells FDA voucher for $195M to support neurodegenerative pipeline pharminent June 19, 2026
